Last reviewed 2026-06-02 · How we verify

Acetalozamide

China Medical University Hospital · Phase 2 active Small molecule ✓ Verified Jun 2026

Acetalozamide is a Small molecule drug developed by China Medical University Hospital. It is currently in Phase 2 development.

Acetalozamide is being studied as a potential treatment for Acute Mountain Sickness (AMS) in a clinical trial. The trial is evaluating the effectiveness of Acetalozamide in comparison to Chinese Medicine for the prevention and treatment of high altitude illness.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Acetalozamide
Sponsor	China Medical University Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Acetalozamide CI brief — competitive landscape report
Acetalozamide updates RSS · CI watch RSS
China Medical University Hospital portfolio CI

Frequently asked questions about Acetalozamide

What is Acetalozamide?

Acetalozamide is a Small molecule drug developed by China Medical University Hospital.

Who makes Acetalozamide?

Acetalozamide is developed by China Medical University Hospital (see full China Medical University Hospital pipeline at /company/china-medical-university-hospital).

What development phase is Acetalozamide in?

Acetalozamide is in Phase 2.

Manufacturer: China Medical University Hospital — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing